TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an update.
Rhythm Biosciences Ltd. announced a change in the director’s interest, with Sue MacLeman acquiring 450,000 loan funded shares and 450,000 unlisted options, while disposing of 200,000 unlisted options. This change, approved by shareholders at the Annual General Meeting, reflects a strategic adjustment in the company’s governance and may impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd. operates in the biotechnology industry, focusing on the development and commercialization of medical diagnostics. The company is known for its innovative products aimed at improving early detection and treatment of diseases, with a particular emphasis on cancer diagnostics.
Average Trading Volume: 343,535
Technical Sentiment Signal: Buy
Current Market Cap: A$28.99M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.